Search research articles
Contact Us
Filters
Showing results (71-80 of 86) with videos related to
Page
of 9
Sort By:
JACC. Heart Failure
|
March 7, 2023
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
Peter Carson, John R Teerlink, Michel Komajda, et al.
European Journal of Endocrinology
|
September 19, 2025
World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC
Dorothee Rogoll, Laura-Sophie Landwehr, Jochen Schreiner, et al.
Circulation
|
August 30, 2021
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
Milton Packer, Javed Butler, Faiez Zannad, et al.
Clinical Kidney Journal
|
February 10, 2021
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
Christoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
Clinical Kidney Journal
|
September 3, 2021
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
Christoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
Circulation
|
October 21, 2020
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
Milton Packer, Stefan D Anker, Javed Butler, et al.
Circulation
|
December 28, 2018
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K McGuire, John H Alexander, Odd Erik Johansen, et al.
Diabetes Care
|
May 24, 2020
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Vlado Perkovic, Robert Toto, Mark E Cooper, et al.
Hemasphere
|
November 15, 2019
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study
Klaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.
Journal of the American Society of Nephrology : JASN
|
May 14, 2015
ADCK4-Associated Glomerulopathy Causes Adolescence-Onset FSGS
Emine Korkmaz, Beata S Lipska-Ziętkiewicz, Olivia Boyer, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 86) with videos related to
Sort By:
Page
of 9
JACC. Heart Failure
|
March 7, 2023
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
Peter Carson, John R Teerlink, Michel Komajda, et al.
European Journal of Endocrinology
|
September 19, 2025
World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC
Dorothee Rogoll, Laura-Sophie Landwehr, Jochen Schreiner, et al.
Circulation
|
August 30, 2021
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
Milton Packer, Javed Butler, Faiez Zannad, et al.
Clinical Kidney Journal
|
February 10, 2021
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
Christoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
Clinical Kidney Journal
|
September 3, 2021
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
Christoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
Circulation
|
October 21, 2020
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
Milton Packer, Stefan D Anker, Javed Butler, et al.
Circulation
|
December 28, 2018
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K McGuire, John H Alexander, Odd Erik Johansen, et al.
Diabetes Care
|
May 24, 2020
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Vlado Perkovic, Robert Toto, Mark E Cooper, et al.
Hemasphere
|
November 15, 2019
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study
Klaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.
Journal of the American Society of Nephrology : JASN
|
May 14, 2015
ADCK4-Associated Glomerulopathy Causes Adolescence-Onset FSGS
Emine Korkmaz, Beata S Lipska-Ziętkiewicz, Olivia Boyer, et al.
Page
of 9